论文部分内容阅读
目的探讨肺脑合剂治疗Ⅱ型呼吸衰竭的临床疗效。方法 82例Ⅱ型呼吸衰竭患者,随机分为研究组和对照组,各41例。对照组行强心、吸氧、平喘等常规治疗,研究组行常规治疗+肺脑合剂治疗。统计对比两组血气分析变化、临床疗效。结果 1血气分析变化。治疗前,两组二氧化碳分压(Pa CO2)、动脉血氧分压(Pa O2)比较差异无统计学意义(P>0.05);治疗后,研究组Pa CO2、Pa O2情况优于对照组,差异有统计学意义(P<0.05)。2临床疗效。比较两组临床疗效,研究组总有效率(37/41,90.24%)比对照组(33/41,80.49%)高,差异有统计学意义(P<0.05)。结论应用肺脑合剂治疗Ⅱ型呼吸衰竭,可有效改善患者的血气分析,增强治疗效果,值得推广应用。
Objective To investigate the clinical efficacy of “Feiluo Mixture” in treating type Ⅱ respiratory failure. Methods 82 cases of type Ⅱ respiratory failure patients were randomly divided into study group and control group, 41 cases in each group. Control group cardiac, oxygen, asthma and other conventional treatment, the study group conventional treatment + pulmonary brain mixture therapy. Statistical comparison of two groups of blood gas analysis changes, clinical efficacy. Results 1 Blood gas analysis changes. Before treatment, there was no significant difference in PaCO 2 and PaO 2 between the two groups (P> 0.05). After treatment, PaCO 2 and PaO 2 in the study group were better than those in the control group, The difference was statistically significant (P <0.05). 2 clinical efficacy. The total effective rate (37/41, 90.24%) in the study group was significantly higher than that in the control group (33/41, 80.49%). The difference was statistically significant (P <0.05). Conclusion The application of Feiluo Mixture in the treatment of type Ⅱ respiratory failure can effectively improve the blood gas analysis of patients and enhance the therapeutic effect, which is worth popularizing and applying.